Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 4/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905652 | 0.88 | L3MBTL1 (0.46) | L3MBTL1KAT6AGLO1SLC40A1EGFR | |
| SCHEMBL4425842 | 0.83 | MEN1 (0.51) | EGFRKDM4E | |
| SCHEMBL4421984 | 0.83 | EGFR (0.53) | L3MBTL1GLO1EGFRPKMPTGS1 | |
| SCHEMBL4422634 | 0.81 | CYP2D6 (0.43) | GLO1KDM4EPKMALDH1A1 | |
| SCHEMBL4425255 | 0.80 | EGFR (0.35) | EGFRPTGS1PTGS2 | |
| SCHEMBL4421005 | 0.80 | EGFR (0.35) | EGFRALDH1A1 | |
| SCHEMBL4433510 | 0.79 | TSHR (0.47) | SLC40A1ALDH1A1 | |
| SCHEMBL4426700 | 0.77 | MAPT (0.46) | KDM4EALDH1A1 | |
| SCHEMBL4427092 | 0.77 | L3MBTL1 (0.58) | L3MBTL1KAT6AGLO1SLC40A1METAP2 | |
| SCHEMBL4425868 | 0.76 | PRKD3 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514556-B2 | Inhibitors of β-lactamase | METHYLGENE INC. (CA) | 2009-04-07 | — | — | US | disclosed |
| US-20070293675-A1 | Novel Inhibitors Of Beta-Lactamase | METHYLGENE, INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-7259172-B2 | phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance | METHYLGENE INC. (CA) | 2007-08-21 | — | — | US | disclosed |
| US-20060105999-A1 | Novel inhibitors of beta-lactamase | METHYLGENE, INC. (CA) | 2006-05-18 | — | — | US | disclosed |
| US-7030103-B2 | Sulfonamidomethyl phosphonate inhibitors of β-lactamase | METHYLGENE, INC. (CA) | 2006-04-18 | — | — | US | disclosed |
| EP-1194436-B1 | SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC (CA) | 2005-11-30 | — | — | EP | disclosed |
| US-6921756-B2 | Inhibitors of β-lactamase | METHYLGENE, INC. (CA) | 2005-07-26 | — | — | US | disclosed |
| US-6884791-B2 | Inhibitors of β-lactamase | METHYLGENE, INC. (CA) | 2005-04-26 | — | — | US | disclosed |
| US-20050043276-A1 | Novel inhibitors of beta-lactamase | METHYLGENE, INC. (CA) | 2005-02-24 | — | — | US | disclosed |
| US-20040082546-A1 | Novel Inhibitors of beta-lactamase | METHYLGENE, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040059115-A1 | Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase | 92229129 QUEBEC INC. (CA) | 2004-03-25 | — | — | US | disclosed |
| US-20040029836-A1 | Novel inhibitors of beta-lactamase | 92229129 QUEBEC INC. (CA) | 2004-02-12 | — | — | US | disclosed |
| US-6472406-B1 | Sulfonamidomethyl phosphonate inhibitors of beta-lactamase | METHYLGENE, INC. (CA) | 2002-10-29 | — | — | US | disclosed |
| EP-1194436-A1 | SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE | Methylgene, Inc. (CA) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001002411-A1 | SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE | METHYLGENE INC. (CA) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043276-A1 | Novel inhibitors of beta-lactamase | MGAM, LSS, CYP51A1 | L3MBTL1 1302/4885KAT6A 3840/4885GLO1 151/4885 |
| US-20040029836-A1 | Novel inhibitors of beta-lactamase | LSS, MGAM, COASY | L3MBTL1 1385/4885KAT6A 3742/4885GLO1 161/4885 |
| US-20060105999-A1 | Novel inhibitors of beta-lactamase | LSS, MGAM, LCT | L3MBTL1 1338/4885KAT6A 3660/4885GLO1 117/4885 |
| US-20040059115-A1 | Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase | PGLS, MGAM, STS | L3MBTL1 1328/4885KAT6A 2677/4885GLO1 568/4885 |
| US-20070293675-A1 | Novel Inhibitors Of Beta-Lactamase | MGAM, LSS, CYP51A1 | L3MBTL1 1302/4885KAT6A 3840/4885GLO1 151/4885 |
| US-20040082546-A1 | Novel Inhibitors of beta-lactamase | LSS, MGAM, COASY | L3MBTL1 1305/4885KAT6A 3615/4885GLO1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.